difelikefalin

peripherally restricted and selective agonist of kappa opioid receptors

Also Known As:

4-Piperidinecarboxylic acid, 4-amino-1-((2R)-6-amino-2-(((2R)-2-(((2R)-2-(((2R)-2-amino-1-oxo-3-phenylpropyl)amino)-1-oxo-3-phenylpropyl)amino)-4-methyl-1-oxopentyl)amino)-1-oxohexyl)-; Korsuva; N-((2R)-1-(((2R)-1-(((2R)-6-Amino-1-(4-amino-4-carboxy-1-piperidinyl)-1-oxo-2-hexanyl)amino)-4-methyl-1-oxo-2-pentanyl)amino)-1-oxo-3-phenyl-2-propanyl)-D-phenylalaninamide

Networked: 37 relevant articles (6 outcomes, 14 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Piperidines: 17
    - difelikefalin: 37

Experts

1.	Menzaghi, Frédérique: 3 articles (01/2022 - 01/2020)
2.	Fishbane, Steven: 3 articles (05/2020 - 01/2020)
3.	Munera, Catherine L: 2 articles (01/2022 - 01/2021)
4.	Spencer, Robert H: 2 articles (01/2022 - 05/2020)
5.	Munera, Catherine: 2 articles (05/2020 - 01/2020)
6.	Chisolm, Sarah: 1 article (06/2022)
7.	Elmariah, Sarina: 1 article (06/2022)
8.	Kwatra, Shawn G: 1 article (06/2022)
9.	Sciascia, Thomas: 1 article (06/2022)
10.	Ko, Mei-Ju: 1 article (05/2022)

Related Diseases

1.	Pruritus (Itching) 07/28/2022 - "The analyzed clinical trials showed that difelikefalin was effective in reducing pruritus in patients as assessed by the Worst Itching Intensity Numerical Rating Scale. " 05/01/2020 - "In this trial, difelikefalin effectively reduced itching intensity and improved sleep and itch-related quality of life." 01/01/2023 - "In this phase 2, double-blind, placebo-controlled trial, we randomly assigned, in a 1:1 ratio, patients with moderate-to-severe pruritus caused by notalgia paresthetica to receive 2 mg of oral difelikefalin or placebo twice daily for 8 weeks. " 10/01/2022 - "Study 3105 was conducted to further assess the safety of difelikefalin and the effects on pruritus and QoL. " 07/28/2022 - "A systematic review of currently available clinical trials was performed to assess the efficacy and safety of difelikefalin in patients with uremic pruritus. "
2.	Chronic Renal Insufficiency 07/28/2022 - "Due to its proven efficacy and good safety profile, difelikefalin is a promising drug for the treatment of pruritus in patients with chronic kidney disease." 01/01/2023 - "A phase 2 study of oral difelikefalin in subjects with chronic kidney disease and moderate-to-severe pruritus." 01/01/2023 - "Clinical trials and articles evaluating difelikefalin for chronic kidney disease-associated pruritis (CKD-aP) in HD patients. " 04/05/2023 - "The first real-world experience of IV difelikefalin to treat chronic kidney disease-associated pruritus in haemodialysis patients." 07/28/2022 - "Difelikefalin in the Treatment of Chronic Kidney Disease-Associated Pruritus: A Systematic Review."
3.	Renal Insufficiency (Renal Failure) 01/01/2023 - "Two phase III studies (KALM-1 and KALM-2) of difelikefalin showed reduced CKD-aP severity and improved itch-related health-related quality of life in patients with moderate and severe CKD-aP receiving haemodialysis for kidney failure. " 01/01/2023 - "We aimed to estimate the cost effectiveness of difelikefalin for patients with CKD-aP receiving haemodialysis for kidney failure compared to standard care from a UK National Health Service perspective. " 01/01/2023 - "Cost Effectiveness of Difelikefalin Compared to Standard Care for Treating Chronic Kidney Disease Associated Pruritus (CKD-aP) in People with Kidney Failure Receiving Haemodialysis."
4.	Kidney Diseases (Kidney Disease) 01/01/2023 - "It includes the use of skin emollients, optimization of dialysis parameters and management of chronic kidney disease complications, and specifically the use of difelikefalin. "
5.	Atopic Dermatitis (Atopic Eczema) 10/01/2023 - "Difelikefalin (DFK) has been found to reduce itch in various chronic pruritic conditions, including atopic dermatitis (AD). " 10/01/2023 - "Difelikefalin suppresses itch and reduces scratching independent of inflammation in a murine model of atopic dermatitis." 11/01/2021 - "Clinical studies of an oral formulation of difelikefalin have also been completed or are underway in pruritus indications, including pruritus associated with atopic dermatitis, notalgia paraesthetica or primary biliary cholangitis. " 10/01/2023 - "Oral difelikefalin reduces moderate to severe pruritus and expression of pruritic and inflammatory biomarkers in subjects with atopic dermatitis."

Related Drugs and Biologics

1.	TRK 820
2.	Emollients
3.	kappa Opioid Receptors (kappa Opioid Receptor)
4.	Nalbuphine (Nubain)
5.	Naltrexone (ReVia)
6.	Butorphanol (BC 2627)
7.	Antipruritics
8.	difelikefalin
9.	Opioid Receptors (Opioid Receptor)
10.	Biomarkers (Surrogate Marker)

Related Therapies and Procedures

1.	Renal Dialysis (Hemodialysis)
2.	Therapeutics